NCT00315627已完成2 期
Steroid-free and Long-term Calcineurin-free Trial in Islet Cell Transplantation
Rodolfo Alejandro1 个研究点 分布在 1 个国家目标入组 3 人开始时间: 2005年7月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 3
- 试验地点
- 1
- 主要终点
- Measurement of Glycemic Control by HbA1c and Prevention of Severe Hypoglycemia
研究概览
简要总结
The purposes of this study are:
- To reverse hyperglycemia and insulin dependency in patients with type 1 diabetes mellitus through islet transplantation utilizing steroid free, calcineurin-inhibitor free immunosuppression.
- To assess the long-term function of successful islet transplants in patients with type 1 diabetes mellitus utilizing islets that have undergone a period of culture.
- To determine whether the natural history of the microvascular, macrovascular, and neuropathic complications are altered following the successful transplantation of islets.
详细描述
STUDY DESIGN:
The initial proposal submitted to the JDRFI was to compare 3 different groups of patients receiving islet cell transplants utilizing steroid-free, calcineurin-free protocols. The 3 groups were as follows:
- Zenapax, Rapamycin & MMF
- Campath, Rapamycin & MMF, and
- Thymoglobulin, Rapamycin & MMF.
The grant was awarded in December 2003, however the recommendations were to focus on a single group (group 3 or 4) in order to determine the relative efficacy and toxicity of a new immunosuppressive drug combination. We elected to perform the group utilizing Campath, since we have a similar protocol utilizing the same immunosuppressive regimen with the addition of CD34+ enriched donor bone marrow cells (2000/0024). The results of this trial utilizing a steroid-free/calcineurin-free protocol will be compared with the standard "Edmonton Protocol" (2000/0196), which we are currently conducting (14 patients have been transplanted). In addition, the results will be compared with those in 2000/0024.
Protocol 2000/0024 (utilizing the same immunosuppressive regimen; Campath, Rapamycin, Tacrolimus-switched to MMF at 3 months) is being followed by a DSMB established at the NIH.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Potential candidates must have type 1 diabetes mellitus and fulfill one or more of the following:
- •Manifest signs and symptoms that are severe enough to be incapacitating. Incapacitating signs and symptoms include hypoglycemic episodes requiring assistance by others and hypoglycemia unawareness (the inability to recognize low blood glucoses; glucoses < 54 mg/dl). These patients are at high risk for involvement in accidents (they can lose consciousness or act irrationally), thus causing harm to themselves and/or others.
- •Patients with poor diabetes control (HbA1c > 8.0% but < 12%), despite intensive insulin therapy, as defined by: self monitoring of blood glucose ≥ 4 times/day, multiple insulin injections (≥ 3/day) or insulin pump, and close monitoring of blood glucose control by an endocrinologist. These patients can experience acute, rapid hyperglycemia secondary to several stress factors, that can lead to dehydration, disorientation, and in some instances, ketoacidosis.
- •Progressive diabetic complications. These patients with chronically poor glycemic control are at higher risk for the development of a wide variety of complications (retinopathy, neuropathy, nephropathy, and cardiovascular disease) associated with diabetes.
排除标准
- •Potential candidates will be excluded as per the following criteria:
- •Age < 18 or > 65 years
- •Duration of diabetes < 5 years
- •Do not have a physician that is monitoring diabetes for > 6 months
- •Body mass index > 26
- •Weight > 80 kg
- •Insulin requirement > 1.0 u/kg/d
- •HbA1c > 12%
- •Stimulated or basal C-peptide > 0.3 ng/ml
- •Corrected creatinine clearance < 60 ml/min
- •Serum creatinine consistently above 1.6 mg/dl
- •Macroalbuminuria (> 300 mg/24 hours)
- •Anemia (hemoglobin < 12.0 g/dl for males; < 11 g/dl for females)
- •Hyperlipidemia (fasting low-density lipoprotein [LDL] cholesterol > 130 mg/dl and/or fasting triglycerides > 200 mg/dl)
- •Abnormal liver function tests (consistently > 1.5 x normal range)
- •Serological evidence of HIV, HBsAg and/or HBcAb, HBsAb without history of vaccination, human t cell lymphotropic virus 1 (HTLV-1), or hepatitis C virus (HCV)
- •Negative serology for Epstein-Barr virus (EBV) or evidence of acute or chronic infection (IgM ≥ IgG)
- •Lack of updated immunizations per current Centers for Disease Control (CDC) guidelines (including lack of immunization against hepatitis B, pneumococcus and influenza - during season)
- •Presence of panel reactive antibodies > 20%
- •Prostate-specific antigen (PSA) > 4 ng/ml unless malignancy is ruled out
- •Positive tuberculin test (unless proof of adequate treatment for latent tuberculosis can be provided)
- •X-ray evidence of pulmonary infection or other significant pathology
- •Gall stones and/or portal hypertension and/or hemangioma on liver ultrasound
- •Abnormal abdominal or pelvic ultrasound (evidence of masses that are considered suspicious for malignancy or adenopathy)
- •Active peptic ulcer disease
- •Active infections
- •Unstable cardiovascular status (including positive stress echocardiography if age > 35)
- •Untreated or unstable proliferative diabetic retinopathy
- •Previous/concurrent organ transplantation (except for failed islet cell or pancreas transplantation)
- •Malignancy or previous malignancy
- •Any medical condition requiring chronic use of steroids
- •Active alcohol or substance abuse; smoking in the last 6 months.
- •Sexually active females who are not:
- •post-menopausal,
- •surgically sterile, or
- •not using an acceptable method of contraception (oral contraceptives, Norplant, Depo-Provera, and barrier devices with spermicide are acceptable; condoms used alone are not acceptable)
- •Positive pregnancy test or intent for future pregnancy, or male subject's intent to procreate
- •Any condition or any circumstances that make it unsafe to undergo an islet cell transplant
- •Psychogenically unable to comply
- •Failed psychological evaluation
- •Persistent leukopenia (white blood cell count < 3,000/uL on more than 3 occasions)
研究组 & 干预措施
islet transplantation
Experimental
Islet Alone Transplantation under Alentuzumab (Campath1H) induction.
干预措施: Islet transplantation (Drug)
结局指标
主要结局
Measurement of Glycemic Control by HbA1c and Prevention of Severe Hypoglycemia
时间窗: 1 year
Number of subjects at 1 year with HbA1c \< 6.5% and absence of severe hypoglycemia
次要结局
- Improvement in Metabolic Control as Evidenced by Hemoglobin A1c < 6.5%(1 year)
- Restoration of Hypoglycemia Awareness 1 Year After Transplantation(1 year)
- Elimination of Severe Hypoglycemia(1 year)
- Islet Allograft Function(1 year)
研究者
Rodolfo Alejandro
Professor of Medicine
University of Miami
研究点 (1)
Loading locations...
相似试验
已完成
2 期
A Clinical Trial to Prevent the Complications of Insulin Resistance (Including Type-2 Diabetes)Insulin ResistanceDiabetes MellitusNCT00015626National Center for Research Resources (NCRR)300
Unknown
4 期
Flexible Insulin Therapy Untethered Insulin Regimen in Avidly Exercising Patients With Type 1 Diabetes: FIT UntetheredType 1 Diabetes MellitusNCT03838783LMC Diabetes & Endocrinology Ltd.30
Unknown
4 期
Intensive Insulin for Severe/Moderate Hypertriglyceridemia Pancreatitis.Acute PancreatitisHypertriglyceridemiaNCT03501680First Affiliated Hospital of Wenzhou Medical University200
招募中
不适用
Gfree - For Improved Blood Sugar and Reduced Inflammation.AutoimmunityMetabolic DiseaseDiabetesCeliac DiseaseNCT05894746Göteborg University60
已完成
4 期
Remission Evaluation of Metabolic Interventions in Type 2 Diabetes (REMIT Pilot Trial)Type 2 Diabetes MellitusNCT01181674Population Health Research Institute83